OliX’s robust nonalcoholic hepatitis (NASH) program, OLX702A, targets a gene stemming from genome-wide association studies (GWAS). In addition to improving the fatty liver, hepatic steatosis, and fibrosis, OliX is expanding the drug indication to obesity. NASH is the most common liver disease worldwide with no treatment, giving it promising market potential.
* GWAS: This is a study analyzing the correlation between the specific disease and the nucleic sequence, conducted on a large-scale population of 450,000 individuals. It provides statistically significant genetic data.
Target RNA: Undisclosed
Administration Route: Subcutaneous Injection
Non-alcoholic Steatohepatitis (NASH)
NASH is a liver condition characterized by the accumulation of liver fat, inflammation, and hepatocellular damage, regardless of heavy alcohol use. If left untreated, the condition can aggravate to cause fibrosis, cirrhosis, and even liver cancer. NASH often coexists with other metabolic disorders such as obesity, diabetes, and dyslipidemia. While liver fibrosis was considered irreversible, recent studies suggest that robust therapeutics may revert fibrous tissues to normal.
- Excellent efficacy in NASH/Fibrosis mouse model
- Efficacy verified in NASH NHP model
- Plan to file IND, 2023
- 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)
- 2022 OTS (Oligonucleotide Therapeutics Society) (22.10)